Table 1. Characteristics of HIV-infected subjects.

Subject	Age(yrs)	Gender	Duration of diagnosed HIV infection (mo)	CurrentCD4 count(cells/uL)	CurrentHIV VL(copies/mL)	Nadir CD4 count(cells/uL)	Duration of ART (mo)	Current HAART	Lifetime HAART	Biopsy COX defect (%)
1	55	M	96	503	<40	117	48	TDF FTC ATV/r	TDF FTC ATV/r	0.0%
2	71	M	119	448	<40	UK	119	TDF FTC EFV	ddI AZT 3TC EFV TDF FTC	3.0%
3	74	F	201	825	<40	UK	103	TDF FTC EFV	AZT ddi d4T SQV TDF 3TC EFV	0.4%
4	45	F	71	537	<40	10	70	TDF FTC NVP	AZT 3TC EFV TDF FTC NVP	0.1%
5	55	F	59	406	<40	112	22	TDF FTC AZT DRV/r	TDF FTC LPV/r AZT DRV/r	0.8%
6	63	M	76	783	<40	169	76	ABC 3TC EFV	AZT ABC 3TC EFV	0.0%
7	63	M	215	361	<40	UK	198	ABC 3TC NVP	AZT ddI d4T 3TC ddC IDV NVP ABC	2.2%
8	62	M	43	180	<40	56	42	TDF FTC NVP	TDF FTC NVP	0.2%
9	49	M	193	762	<40	120	193	TDF FTC ATV/r	AZT ddC ddI 3TC d4T SQV NVP IDV NFV ABC TDFLPV/r FTC ATV/r	1.3%
10	48	M	158	872	<40	10	151	TDF ABC NVP	AZT ddI d4T 3TC RTV NVP IDV ddC ABC ATV/r TDF	4.9%
11	60	F	146	666	<40	99	145	ABC 3TC EFV	d4T ABC 3TC EFV	0.2%
12	51	M	141	494	<40	151	140	AZT 3TC NVP	AZT 3TC NVP	1.4%
13	66	M	57	403	<40	287	12	TDF FTC EFV	TDF FTC EFV	11.2%
14	63	F	182	865	<40	300	154	TDF FTC EFV	d4T 3TC NVP NFV EFV AZT TDF FTC	1.2%
15	60	M	101	419	<40	UK	98	TDF FTC NVP	AZT 3TC EFV NVP TDF FTC	2.4%
16	61	M	262	422	<40	UK	160	ABC NVP LPV/r	SQV AZT ddC 3TC d4T ddI IDV ABC NVP NFV LPV/r	0.8%
17	54	M	66	603	<40	244	25	TDF FTC DRV/r	TDF FTC EFV DRV/r	3.4%
18	51	M	237	559	<40	327	165	TDF FTC EFV	AZT ddI RTV NFV TDF FTC EFV	1.5%
19	62	M	143	329	<40	163	55	TDF FTC DRV/r	AZT 3TC NVP FOS-APV RTV TDF FTC DRV/r	1.2%
20	50	F	120	1358	<40	541	0	nil	nil	0.0%
21	53	M	UK	804	<40	301	48	TDF FTC EFV	TDF FTC EFV	NA
22	56	M	240	401	97	150	224	TDF FTC ETR DRV/r	AZT ddC SQV 3TC IDV d4T NVP ddI ABC LPV/r TDFATV/r FOS-APV/r DRV/r MVC FTC	2.2%
23	45	M	165	592	<40	305	146	RAL ABC ATV/r	d4T 3TC NVP ddI IDV ABC ATV/r RAL	9.8%
24	57	M	145	435	<40	379	21	TDF FTC EFV	TDF FTC EFV	0.4%

VL, plasma HIV-1 RNA viral load; (c)ART, (combination) anti-retroviral therapy; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; FOS-APV, fosamprenavir; RTV, ritonavir at therapeutic dose;/r, ritonavir at pharmacokinetic boosting dose; MVC, maraviroc; RAL, raltegravir; UK, unknown; NA, not available; COX, cytochrome c oxidase. COX data (but not MRS data) from 5 subjects has been previously described [8].